Evaluation of FASTPlaqueTB to diagnose smear-negative tuberculosis in a peripheral clinic in Kenya by Bonnet, M et al.
INT J TUBERC LUNG DIS 13(9):1112–1118
©      2009 The Union
Evaluation of FASTPlaqueTBTM to diagnose smear-negative 
tuberculosis in a peripheral clinic in Kenya
M. Bonnet,* L. Gagnidze,* F. Varaine,† A. Ramsay,‡§ W. Githui,¶ P. J. Guerin*
* Epicentre, Paris,  † Médecins Sans Frontières, Paris, France; ‡ Liverpool School of Tropical Medicine, Liverpool, UK; 
§ United Nations Children’s Fund/United Nations Development Programme/World Bank/World Health Organization 
Special Programme for Research and Training for Tropical Diseases (TDR), Geneva, Switzerland; ¶ Centre for Respiratory 
Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya
Correspondence to: Maryline Bonnet, Epicentre (Médecins Sans Frontières), Rue de Lausanne 78, CH-1211 Genève 21, 
Switzerland. Tel: (+41) 2 22 849 89 40. e-mail: maryline.bonnet@geneva.msf.org
Article submitted 30 November 2008. Final version accepted 6 April 2009.
OBJECTIVE: To evaluate the performance and feasibility 
of FASTPlaqueTB™ in smear-negative tuberculosis (TB) 
suspects in a peripheral clinic after laboratory upgrading.
DESIGN: Patients with cough ⩾2 weeks, two sputum 
smear-negative results, no response to 1 week of amoxi-
cillin and abnormal chest X-ray were defi  ned as smear-
negative suspects. One sputum sample was collected, de-
contaminated and divided into two: half was tested with 
FASTPlaqueTB in the clinic laboratory and the other 
half was cultured on Löwenstein-Jensen medium in the 
Kenyan Medical Research Institute. Test sensitivity and 
specifi  city were evaluated in all patients and in human 
immunodefi  ciency virus (HIV) infected patients. Feasi-
bility was assessed by the contamination rate and the re-
sources required to upgrade the laboratory.
RESULTS:  Of 208 patients included in the study, 56.2% 
were HIV-infected. Of 203 FASTPlaqueTB tests, 95 
(46.8%) were contaminated, which interfered with result 
interpretation and led to the interruption of the study. 
Sensitivity and specifi  city were respectively 31.2% (95%CI 
12.1–58.5) and 94.9% (95%CI 86.8–98.4) in all pa-
tients and 33.3% (95%CI 9.9–65.1) and 93.9% (95%CI 
83.1–98.7) in HIV-infected patients. Upgrading the lab-
oratory cost €20 000.
CONCLUSION:  FASTPlaqueTB did not perform satis-
factorily in this setting. If contamination can be reduced, 
in addition to laboratory upgrading, its introduction in 
peripheral clinics would require further assessment in 
smear-negative and HIV co-infected patients and test ad-
aptation for friendlier use.
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IN COUNTRIES with limited laboratory capacity, 
the diagnosis of pulmonary tuberculosis (TB) is based 
on direct sputum smear microscopy following World 
Health Organization (WHO) and International Union 
Against Tuberculosis and Lung Disease (The Union) 
guidelines.1,2 Microscopy is inexpensive, but it has low 
sensitivity, particularly in human immunodefi  ciency 
virus (HIV) co-infected patients.3 This is unfortunately 
the only bacteriological test available in peripheral 
health clinics in resource-poor countries, where the 
majority of patients seek care. More sensitive methods, 
such as Mycobacterium tuberculosis culture, are only 
available in referral laboratories. Diagnosis of smear-
negative TB patients is empirically based on the use 
of algorithms that consider radiological signs and re-
sponse to antibiotic treatment. The performance of al-
gorithms in HIV-infected patients is poor,4,5 resulting 
in delayed treatment, compromised prognosis and 
prolonged TB transmission.6
Although several promising diagnostic tests are 
in the development pipeline, few are likely to be suit-
able for microscopy laboratories in the short to me-
dium term.7,8 FASTPlaqueTBTM (Biotec Laboratory 
Ltd, Ipswich, UK), a test based on the use of myco-
bacteriophages to refl  ect the presence of viable M. tu-
berculosis in sputum specimens (detection threshold 
of about 100 bacilli), was identifi  ed as a potential 
alternative for diagnosing smear-negative TB.9 Ac-
cording to the manufacturer, this test can deliver re-
sults within 48 h and is relatively cheap (€2.50/test). 
Some studies have reported a sensitivity of between 
50% and 75% and a specifi  city of 98% in smear-
negative TB suspects.10,11 The authors suggest a role 
for this test in the early diagnosis of clinically sus-
pected smear-negative cases.12,13 Evaluations to date 
have been conducted only in university or reference 
laboratories.9
Given the lack of appropriate diagnostics for use 
in basic laboratories, we upgraded a peripheral labo-
ratory to make it more appropriate for more advanced 
testing, and conducted a prospective fi  eld evaluation 
of the performance and feasibility of FASTPlaqueTB 
to diagnose smear-negative TB patients under opera-
tional conditions.
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METHODS
Participants
Study participants were recruited in an urban out-pa-
tient clinic supported by the Kenyan Ministry of Health 
and Médecins Sans Frontières (MSF), which provides 
HIV and TB care to the community living in the slum 
of Mathare, Nairobi City, Kenya. In 2001, the HIV 
prevalence in the adult population of Nairobi was esti-
mated at 15%, while 50% of TB patients were HIV 
co-infected.14 Consecutive patients aged >15 years with 
cough >2 weeks were screened with sputum smear mi-
croscopy. Only those defi  ned as smear-negative pulmo-
nary TB suspects based on the combination of two 
Ziehl-Neelsen (ZN) smear-negative results, no clinical 
response to a 1-week trial of amoxicillin and abnormal 
chest X-ray (CXR) were eligible for the study.15 A sug-
gestive CXR was defi  ned as the presence of pleural ef-
fusion, lymphadenopathy, cavity or miliary.15 Exclusion 
criteria were intake of anti-tuberculosis drugs or qui-
nolones in the 4 weeks before screening and episodes 
of moderate to severe haemoptysis (⩾50 ml) in the last 
7 days. Demographic information, treatment history 
and clinical characteristics were recorded through pa-
tient interview. Pre- and post-HIV test counselling was 
offered to all those patients included in the study. Free 
HIV care was available, including antiretroviral treat-
ment if indicated, based on CD4 cell count.
Approval for the study was provided by the Na-
tional Ethical Review Committee of the Kenyan Re-
search Institute (KEMRI, Nairobi, Kenya) and the 
Comité de Protection des Personnes (Ile-de-France 
XI, France). Written informed consent was obtained 
from each subject.
Laboratory methods
M. tuberculosis culture on Löwenstein-Jensen (LJ) me-
dium was used as the reference standard for this eval-
uation, and was performed in the KEMRI Mycobac-
teriology Laboratory. Eligible patients were required 
to produce a minimum of 1 ml sputum on the spot in 
a 50 ml sterile conical tube after clear instructions had 
been given on how to produce a good quality specimen. 
To prevent the risk of nosocomial transmission, speci-
mens were collected outdoors. Macroscopic appearance 
of the specimen was recorded as ‘purulent’, ‘muco-
purulent’, ‘mucoid’, ‘blood-stained’ or ‘salivary’.
The FASTPlaqueTB kit consists of eight tests and 
one positive and one negative control. FASTPlaqueTB 
requires 3 days from specimen collection to availabil-
ity of results: the fi  rst day for the specimen prepara-
tion, the second day for assay procedure and the third 
day for interpreting the results.  Specimens for FAST-
PlaqueTB were processed in accordance with the man-
ufacturers’ instructions, available on the Biotec web-
site,* except in relation to batching of the specimens: 
due to the small number of eligible patients per day, 
we adapted the manufacturer’s guidelines and pro-
cessed the specimens once a week to reduce waste of 
reagents. Non-decontaminated specimens were there-
fore refrigerated at 4°C until use, and were then de-
contaminated, cultured and processed with FAST-
  PlaqueTB on the same day. The entire specimen was 
decontaminated using N-acetyl-L-cysteine/sodium hy-
droxide  N-acetil-L-cysteine/sodium hydroxide, fol-
lowed by neutralisation with phosphate buffer. For the 
purpose of the study, half of the specimen was trans-
ferred with a sterile pipette to a sterile 50 ml conical 
centrifuge tube to be processed with FASTPlaqueTB, 
and the remaining portion was labelled and sent the 
same day to the KEMRI laboratory for culture. 
The assay procedure started with the mixture of 
the decontaminated specimen with the FASTPlaqueTB 
Medium Plus reagent followed by centrifugation. 
One ml of the suspension was then transferred to a 
labelled reaction vessel and incubated at 37°C over-
night to enrich viable TB bacilli present in the sample. 
On day 2, after enrichment, 0.1 ml of the mycobacte-
riophage solution was added and incubated for 1 h; 
0.1 ml of virucide solution was then added to destroy 
all bacteriophages that had not infected host cells, and 
incubated at room temperature for 5 min; 5 ml FAST-
PlaqueTB Medium Plus was then added to neutralised 
excess virucide, followed by 1 ml of sensor cells. The 
contents of the vessel were added to a sterile Petri dish 
and overlayered with 5 ml molten agar. The plates 
were rotated several times, clockwise and counter-
clockwise, after pouring. These were then allowed to 
set, and were incubated at 37°C overnight. The next 
day, the number of plaques was counted following 
the manufacturer’s recommendations. A cut-off of 
20 plaques was used to defi  ne a positive result. The 
fusion of plaques giving the aspect of confl  uent or 
complete lysis of the lawn of cell growth also defi  ned 
a positive result. Based on the manufacturer’s guide-
lines, contamination was defi  ned as ‘contamination 
that interferes with interpretation’ when the growth 
of contaminating bacteria obscured the lawn of Sen-
sor cell growth and did not allow the interpretation 
of the plate, or ‘contamination that does not interfere 
with interpretation’ when contaminating bacteria were 
present as discrete colonies on the lawn. Safety mea-
sures similar to those required to set up M. tuberculo-
sis culture were followed to process the test, as rec-
ommended by the manufacturer, and safety guidelines 
were introduced for disposal of pathogenic biological 
waste and in case of laboratory accidents.
At KEMRI, the specimens were centrifuged and 
the deposits cultured on LJ media and incubated at 
37°C for up to 8 weeks. The slants were inspected 
weekly. All positive cultures (based on the WHO cul-
ture grading scale) were confi  rmed for presence of 
acid-fast bacilli by ZN microscopy, and strain identifi  -
cation was done using temperature growth range,  * www.biotec.com1114  The   International   Journal   of   Tuberculosis   and   Lung   Disease
pigment production, resistance to p-nitrobenzoic acid 
(500 mg/l) and thioxyphene carboxylic acid hydra-
zide (2 mg/l) and niacin production.16,17
For HIV testing, UniGold (Trinity Biotech, Bray, 
Ireland) and DETERMINE (Inverness Medical, Wal-
tham, MA, USA) tests were performed simultaneously; 
the CAPILLUS test (Cambridge Diagnostics, Galway, 
Ireland) was used in case of discordant results.
Inter- and intra-reader reproducibility was assessed 
by the reading of random selections of plates a sec-
ond time on the same day by a different technician, 
and by the same technician 24 h after the fi  rst reading, 
respectively. The laboratory supervisor masked the plate 
identifi  cation to ensure blind reading. All plates were 
refrigerated at +4°C for 24 h. In addition to this as-
sessment, the study laboratory supervisor reread a 
sample of plates blind within 24 h for internal quality 
control.
A list of parameters was measured to evaluate the 
operational aspects of the test: duration of 1) weekly 
sterilisation of containers and 2) weekly preparation 
of reagent; 3) specimen preparation (day 1 of the speci-
men processing); 4) FASTPlaqueTB assay procedure 
(day 2); and 5) the reading of the plates (day 3). The 
cost of the test and the consumables needed to perform 
FASTPlaqueTB was assessed based on the Kenyan 
market price and within the context of a study.
To perform FASTPlaqueTB, an additional room 
was allocated to the one-roomed microscopy labora-
tory of the health clinic and renovated to create the 
necessary aseptic conditions; a microbiological safety 
cabinet and other requisite equipment were installed 
(centrifuge, incubator, hotplate and automatic pipette); 
electrical power back-up was installed to ensure un-
interrupted overnight incubation; and two smear mi-
croscopy technicians were trained for 2 months in 
aseptic techniques and in the assay procedure.
Statistical methods
Sample size was calculated using an expected sensi-
tivity of FASTPlaqueTB against M. tuberculosis cul-
ture of 50% in smear-negative pulmonary TB suspects, 
10% precision and a risk α of 0.05.9,10 To assert this 
hypothesis, 97 patients positive for M. tuberculosis 
culture were required. With an estimation of 25% 
culture positivity among smear-negative suspects and 
a 15% increase to cover potential dropouts, 450 smear-
negative suspects were required to evaluate the accu-
racy of the test.
Data were double entered using Epidata 3.1 (Epi-
Data Association, Odense, Denmark) and analysed us-
ing SPSS® 11.0 for Windows (SPSS Inc, Chicago, IL, 
USA). Simple proportions and means were calculated 
to present patient and specimen characteristics. The 
χ2 test was used to compare proportion, with P value 
<0.05 to ascertain signifi  cance. Sensitivity, specifi  city, 
predictive values and likelihood ratios were calculated 
to measure the performance of the test in all cases 
and in the subgroup of HIV-infected cases. Positive 
likelihood ratio above 10 and negative like  lihood 
ratio below 0.1 were considered to provide strong 
evidence for rule in or rule out diagnoses.18 Inter- and 
intra-reader reproducibility was assessed by the cal-
culation of the kappa (κ) coeffi  cient, which measures 
the agreement between the two readings. A κ between 
0.80 and 1 signifi  ed an almost perfect agreement.19 
A 95% confi  dence interval (CI) was used to quantify 
uncertainty.
RESULTS
A total of 970 patients with cough for >2 weeks were 
screened between May 2005 and June 2006. Of these, 
208 were smear-negative pulmonary TB suspects (Fig-
ure 1). The characteristics of all patients and the sub-
group of HIV-infected patients are presented in Ta-
bles 1 and 2. Of the 152 patients who accepted HIV 
testing, 117 were HIV-infected (76.9%). Of the 208 
patients included and the 117 HIV-infected patients, 
respectively 114 (54.8%) and 67 (57.3%) had a CXR 
suggestive of TB.17
Of the 208 collected specimens, 161 were purulent 
(77.4%), 42 mucoid (20.2%) and fi  ve bloodstained 
(2.4%). M. tuberculosis culture was performed in 205 
patients (98.6%), of whom 32 (15.6%) had positive 
results, 163 (79.5%) had negative results and 10 
(4.9%) were contaminated. After exclusion of the 
contaminated cultures, 32/195 (16.4%) patients were 
M. tuberculosis culture-confi  rmed. FASTPlaqueTB as-
say procedure failed in fi  ve patients (no addition of 
Sensor cell and absence of media set), which resulted in 
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available tests for 203 patients (97.6%). Among the 
203 plates, 95 (46.8%) presented contamination that 
interfered with interpretation and 71 (35.0%) that 
did not interfere with interpretation, giving an overall 
plate contamination rate of 81.8% (Figure 2). The 
FASTPlaqueTB result was negative in 98 (48.3%) 
cases and positive in 10 (4.9%). Table 3 presents the 
FASTPlaqueTB results according to the culture results.
The unexpectedly high rate of unreadable tests due 
to plate contamination was reported to the study’s 
scientifi  c advisory board, which recommended that 
patient recruitment be discontinued in June 2006, be-
fore the planned sample size was reached.
The cause of contamination was investigated. The 
most common contaminant was an aerobic gram-
positive spore-forming bacillus. Internal quality con-
trol (IQC) measures constantly produced the expected 
results: they included positive and negative control 
plates that did not show any macroscopic or micro-
scopic contamination, ruling out culture medium con-
tamination. Processing sterile distilled water instead 
of specimen did not lead to contamination, suggest-
ing that the contamination source was the specimen 
itself.
After exclusion of contaminated cultures and cases 
with no FASTPlaqueTB results, the proportion of pos-
itive culture results did not signifi  cantly vary between 
patients with interpretable FASTPlaqueTB results (15/ 
88, 17.1%) and those with non-interpretable results 
(16/102, 15.7%, P = 0.8). The test performance could 
therefore be evaluated in 102 patients after exclusion 
of the non-interpretable FASTPlaqueTB results (Ta-
ble 4). The test sensitivity overall was 31.2% (95%CI 
12.1–58.5) and specifi  city was 94.9% (95%CI 86.8–
98.4); they were respectively 33.3% (95%CI 9.9–
65.1) and 93.9% (95%CI 83.1–98.7) in HIV-infected 
patients. Performance was not evaluated in HIV-
negative patients due to the small sample size (n = 18).
Inter- and intra-reader reproducibility was satis-
factory, with a κ of 0.81 (95%CI 0.76–0.84) and 0.92 
(95%CI 0.85–0.94), respectively.
Table 1  Demographic characteristics, TB treatment history 
and HIV status of included patients
Results
VCT, n/N (%)
Positive 117/208 (56.2)
Negative  35/208  (16.8)
Refused testing   56/208 (27.9)
Sex ratio (male/female)
Overall  0.5  (74/134)
HIV-positive  0.4  (31/86)
Age, mean (SD)
Overall 34.5 (10.4)
HIV-positive 34.9 (8.5)
Past TB history, n/N (%)
Overall  60/208  (28.8)
HIV-positive  40/117  (34.2)
TB = tuberculosis; HIV = human immunodeﬁ  ciency virus; VCT = voluntary 
counselling and training; SD = standard deviation.
Table 2  Clinical and radiological presentation of 
included patients
Overall
(N = 208)
n (%)
HIV-positive
(n = 117)
n (%)
Clinical signs
Productive cough 200 (96.1) 110 (90.0)
Chest pain 188 (90.4) 103 (88.0)
Reported fever 182 (87.5) 102 (87.2)
Haemoptysis  24  (11.5)  10  (8.6)
Night sweats 169 (81.2)   97 (82.9)
Reported weigh loss   26 (12.5)   17 (14.7)
Loss of appetite 162 (77.9)   93 (79.5)
Chest X-ray ﬁ  ndings
Cavities  68  (32.7)  40  (34.2)
Inﬁ  ltration 154 (74.0)   96 (82.0)
Condensation 134 (64.4)   73 (62.4)
Pleural  effusion  13  (6.3)   9  (7.7)
Intrathoracic adenopathy   42 (20.2)   24 (20.5)
Miliary   1  (0.5)   1  (0.8)
No  X-ray   2  (1)   1  (0.8)
HIV = human immunodeﬁ  ciency virus.
Figure 2  FASTPlaqueTB results. 
Table 3 Results  of  FASTPlaqueTB by M. tuberculosis culture 
results (N = 208)
FASTPlaqueTB
results
Culture results, n (%)
Positive Negative
Contam-
inated
Not
per-
formed
Positive   5  (15.6)   5  (1.8)  0 0
Negative 11 (34.4)   81 (49.7)   4 (40.0) 2
Indeterminate* 15 (50.0)   73 (47.2)   6 (60.0) 1
Procedure  failure  1   4  0 0
 Total  32 163  10  3
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Considering the operational aspects of FAST-
  PlaqueTB, a median of six specimens (interquartile 
range [IQR] 4–8) were tested per week. The median 
duration of the weekly sterilisation of containers 
was 2.8 h (IQR 2.5–3.1), and it was 2.6 h (IQR 2.3–
3.1) for the weekly preparation of reagents. To per-
form the test itself, the median duration of sputum 
preparation (day 1) was 2.4 h (IQR 2.1–2.5), 2.5 h 
(IQR 2.3–3.0) for the FASTPlaqueTB assay procedure 
(day 2) and 19 s (IQR 15–38) for reading the plate. At 
the time of the study, it cost €7/test to perform FAST-
PlaqueTB, including the cost of the test (€2.5) and the 
cost of other reagents and consumables. Upgrading of 
the peripheral laboratory, together with the service 
and maintenance costs of the additional equipment 
during the study period, amounted to approximately 
€20 000. This fi  gure does not include the costs of ex-
ternal technical assistance.
DISCUSSION
To our knowledge, this is the fi  rst reported study to 
evaluate FASTPlaqueTB in the operational setting of 
a peripheral health clinic. Despite the good storage 
conditions, at +4°C, of specimens between collection 
and processing, strict use of aseptic techniques and 
standard specimen decontamination, as recommended 
by the manufacturer, 80% of the plates were contam-
inated. This resulted in the absence of results for half 
of the patients. The low rate of culture contamination 
(4.9%) indicates that the decontamination was ade-
quate for M. tuberculosis culture on LJ medium but 
not for preventing FASTPlaqueTB contamination. It 
is possible that the delay in processing a batch of 
specimens (up to 1 week) may have contributed to the 
high rates of contamination. Furthermore, most of the 
identifi  ed contaminants were spore-forming bacilli—
an indication of environmental contamination that 
may have occurred during specimen collection, which 
was done outdoors in a dusty environment. This ex-
cessively high contamination rate (40%) has also been 
reported in a previous study conducted in a tertiary 
hospital in Zambia.20
In this study, measurement of the test’s perfor-
mance was limited by the small sample size due to the 
early interruption of the study. The results should 
therefore be interpreted with caution. The sensitivity 
of the test in smear-negative TB suspects, compared 
with LJ culture, is lower (31%, 95%CI 12.1–58.5) 
than that reported in South Africa (54%) and Pakistan 
(77%).10,11,21 Nevertheless, our results are consistent 
with the heterogeneity of sensitivity (13–78%) and 
high specifi  city (89–99%) in smear-negative specimens 
reported by a meta-analysis of bacteriophage-based 
tests.9 The delay in specimen processing of up to 
1 week in our study, and the high proportion of HIV 
infection, could impact the extent of viable mycobac-
teria present in specimens and explain the low sensi-
tivity.9 The positive (5.4) and negative (0.7) likelihood 
ratios did not provide strong evidence that a FAST-
PlaqueTB result can respectively confi  rm or exclude 
TB in smear-negative suspects. These ratios measure 
how a particular test result predicts the risk of abnor-
mality, which is not the case of sensitivity and speci-
fi  city, and are independent of the disease prevalence 
in the sample size, which is another advantage com-
pared to predictive values.18 
Since the study was conducted, the manufacturer 
of FASTPlaqueTB has developed an antimicrobial sup-
plement (NOA: nystatin+oxacillin+aztreonam) to be 
used with the test. This supplement inhibits the growth 
of contaminating bacterial and fungal organisms 
commonly found in respiratory specimens, and sig-
nifi  cantly reduces plate contamination. The test perfor-
mance was not affected when assessed in combina-
tion with the FASTPlaque-Response test for rapid 
identifi  cation of rifampicin (RMP) resistance, but no 
data are available on its use in combination with 
FAST-PlaqueTB.22,23 If the contamination problem can 
be solved without compromising performance, we be-
Table 4  FASTPlaqueTB performance*
Number of cultures
All cases HIV-infected
Positive Negative Total Positive Negative Total
FASTPlaqueTB
  Positive  5  5  10  4  3  7
  Negative 11 81  92  8 46 54
  Total 16 86 102 12 49 61
% (95%CI) % (95%CI)
Sensitivity 31.2 (12.1–58.5) 33.3 (9.9–65.1)
Speciﬁ  city 94.2 (86.9–98.1) 93.9 (83.1–98.7)
Positive predictive value 50.0 (18.7–81.3) 57.1 (18.4–90.1)
Negative predictive value 88.0 (79.6–93.9) 85.2 (72.9–93.4)
Positive likelihood ratio   5.4 (1.8–15.3)   5.5 (1.5–19.1)
Negative likelihood ratio   0.7 (0.5–0.9)   0.7 (0.4–0.9)
* A total of 102 cases were analysed after exclusion of FASTPlaqueTBTM and culture-contaminated results. Of these, 
61 were HIV-positive, 18 HIV-negative and for 23 the HIV status was unknown.
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lieve it may be possible to perform the test in a periph-
eral laboratory that is upgraded. However, upgrading 
a laboratory to the level required to perform the test 
and maintaining it at that level is extremely diffi  cult 
in limited-resource settings, even with the external sup-
port provided in this example. In addition to the cost, 
the installation of specialist equipment, and the require-
ments for uninterrupted overnight electrical power 
for incubation and for equipment maintenance sup-
port present challenges in limited-resource settings.
The study also highlights the limitations of the 
FASTPlaqueTB kits (batch of eight tests) for settings 
with moderate specimen throughput, where specimens 
need to be processed by batch and the delay in pro-
ducing results is therefore increased.
The culture positivity rate among the smear-negative 
TB suspects was relatively low (16%), if we consider 
the high degree of TB suspicion in this study. The rela-
tively low proportion of patients with CXR suggestive 
of TB (54.8%), the high HIV infection rate (56.2%) 
and the high level of microscopy performance reported 
in a previous study conducted in the laboratory during 
the same period, may explain the low culture positiv-
ity.15,24 The male:female sex ratio of smear-negative 
TB suspects was unexpectedly low and should be in-
vestigated further. 
In conclusion, if the problems of contamination 
can be solved, FASTPlaqueTB could be used in the 
few laboratories that already perform M. tuberculosis 
culture in resource-limited countries. The test’s rapid-
ity (2 days) and the possibility of using the same phage-
base method for rapid identifi  cation of RMP suscep-
tibility could provide further reasons for using the 
test. Based on our experience, introducing such a test 
in a peripheral clinic after upgrading the laboratory is 
feasible but expensive, complex and diffi  cult to main-
tain. Several conditions therefore need to be met before 
recommending such an investment: 1) further evalua-
tion of its performance in smear-negative suspects as 
compared to M. tuberculosis culture as well as simple 
methods to optimise smear microscopy, such as the 
specimen concentration method and fl  uorescence mi-
croscopy;25,26 2) considering the relatively high bacilli 
threshold of FASTPlaqueTB, its specifi  city should be 
evaluated in combination to the NOA supplement and 
in HIV-infected patient subgroups, which are more 
likely to have a low bacillary load; 3) several modifi  -
cations, such as the reduction of sample manipula-
tions and the development of smaller kits to be used in 
laboratories conducting only a few tests per day (this 
would allow for daily processing of specimens) could 
make the FASTPlaqueTB more user friendly and 
cost-effective.
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OBJECTIVE :    Evaluer les performances et la faisabilité 
du  FASTPlaqueTB™ chez les patients frottis-négatifs 
suspects de tuberculose dans une clinique périphérique 
après amélioration des capacités du laboratoire. 
MÉTHODES :  Les patients suspects frottis-négatifs étaient 
défi  nis par l’association d’une toux ⩾2 semaines, deux 
résultats de crachats frottis-négatifs, l’absence d’amélio-
ration clinique après 1 semaine d’amoxicilline et une ra-
diographie thoracique anormale. Un crachat était col-
lecté, décontaminé et divisé en deux : une moitié testée 
sur place avec le FASTPlaqueTB et l’autre moitié mise 
en culture sur milieu de Löwenstein-Jensen à l’Institut de 
Recherche médicale de Kenya. La sensibilité et spécifi  cité 
du test étaient évaluées chez tous les patients et chez les 
patients positifs au virus de l’immunodéfi  cience humaine 
(VIH). Le taux de contamination et les ressources néces-
saires à l’introduction du FASTPlaqueTB dans le labo-
ratoire en évaluaient la faisabilité.
RÉSULTATS :    Sur 208 patients inclus, 56,2% étaient 
VIH-positifs. Sur 203 résultats de FASTPlaqueTB, 95 
(46,8%) n’étaient pas interprétables en raison d’une 
contamination, ce qui a conduit à l’interruption de l’étude. 
Le test avait une sensibilité et une spécifi  cité globales de 
31,2% (95%CI 12,1–58,5) et 94,9% (95%CI 86,8–
98,4) et de 33,3% (95%CI 9,9–65,1) et 93,9% (95%CI 
83,1–98,7) chez les patients VIH-positifs. L’amélioration 
des capacités du laboratoire pour l’utilisation du FAST-
PlaqueTB a coûté 20 000€. 
CONCLUSION :  Les  performances  du  FASTPlaqueTB 
sont décevantes dans ce type de contexte. Outre la réduc-
tion du taux de contamination et l’amélioration des ca-
pacités du laboratoire, son utilisation dans une clinique 
périphérique nécessiterait des évaluations supplémen-
taires chez les patients VIH-positifs et frottis-négatifs et 
une optimisation du test pour une meilleure utilisation.
OBJETIVO :  Evaluar el rendimiento diagnóstico y la fac-
tibilidad de la prueba FASTPlaqueTB™ en los consulto-
rios periféricos, en pacientes con presunción diagnóstica 
de tuberculosis (TB) y baciloscopia negativa, una vez op-
timizados los laboratorios.
MÉTODOS :  Se  defi  nieron como casos presuntos de TB 
con baciloscopia negativa, los pacientes con tos de ⩾2 se-
manas de duración y dos baciloscopias negativas, que no 
respondieron al tratamiento de una semana con amoxi-
cilina y que presentaron imágenes anormales en la radio-
grafía de tórax. Se recogió una muestra de esputo y una 
vez descontaminada se dividió en dos alícuotas, una para 
la prueba FASTPlaqueTB en el laboratorio de la clínica 
y otra para cultivo en medio de Löwenstein-Jensen en el 
Instituto de Investigación médica de Kenya. Se evaluó la 
sensibilidad y la especifi  cidad de la prueba en todos los 
pacientes y en los pacientes con infección por el virus de 
la inmunodefi  ciencia humana (VIH). La factibilidad se 
evaluó con respecto a la contaminación y a los recursos 
del laboratorio para la optimización.
RESULTADOS :    De los 208 pacientes incluidos, 56,2% 
presentaron infección por el VIH. De los 203 ensayos 
con FASTPlaqueTB, 95 (46,8%) presentaron una con-
taminación que interfi  rió con la interpretación de los re-
sultados y exigió la interrupción del estudio. La prueba 
demostró una sensibilidad de 31,2% (95%IC 12,1–58,5) 
y una especifi  cidad de 94,9% (IC95% 86,8–98,4) en to-
dos los pacientes y de 33,3% (IC95% 9,9–65,1) y 93,9% 
IC95% 83,1–98,7), respectivamente, en pacientes infecta-
dos por el VIH. La optimización del laboratorio tuvo un 
costo de €20 000. 
CONCLUSIÓN :  La  prueba  FASTPlaqueTB no ofreció 
un rendimiento satisfactorio en este entorno. La introduc-
ción de la prueba en los consultorios periféricos requeri-
ría, además de disminuir el índice de contaminación y el 
costo de optimización del laboratorio, que se practiquen 
nuevas evaluaciones en pacientes con baciloscopia nega-
tiva y coinfección por el VIH y se adapte el ensayo a fi  n 
de facilitar su ejecución.
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